If you have Crohn's disease and are considering Mounjaro for weight management in the UK, the key point is simple: Mounjaro is not licensed to treat Crohn's disease, but Crohn's disease is not listed as a specific contraindication either.
Whether Mounjaro is suitable depends on your individual circumstances, including your Crohn's symptoms, gastrointestinal health, nutritional status and other medicines. If you have active or severe gastrointestinal symptoms, it is especially important to discuss treatment with your prescriber before starting.
For UK adults searching for clear information about "Mounjaro and Crohn's disease", this guide explains what the current prescribing information says, what the research has found so far and what to consider if you have Crohn's disease.
Can You Take Mounjaro If You Have Crohn's?
Crohn's disease is not listed as a specific contraindication to Mounjaro. However, the UK prescribing information says that tirzepatide has not been studied in people with severe gastrointestinal disease, including severe gastroparesis, and should be used with caution in these patients.
This means having Crohn's does not automatically mean that you cannot use Mounjaro. However, your current symptoms and medical history matter.
Someone with Crohn's that is well controlled may have a different risk profile from someone with active symptoms, severe gastrointestinal problems, known strictures or recent bowel surgery. Your prescriber can look at these factors before deciding whether Mounjaro is suitable for you.
Can Mounjaro Cause Crohn's Disease?
There is no evidence that Mounjaro causes Crohn's disease.
Crohn's disease is a type of inflammatory bowel disease, while Mounjaro is a medicine used for type 2 diabetes and weight management. Crohn's is not listed as an adverse reaction or a condition caused by tirzepatide in the current UK prescribing information.
Research into GLP 1 based medicines and inflammatory bowel disease is still developing. A small observational study of people with IBD who used semaglutide or tirzepatide for weight loss found reductions in BMI and body weight, but the study was small and the researchers said that more research is needed on long term safety.
So, these medicines should not be described as a treatment for Crohn's, but current research does not show that tirzepatide causes Crohn's disease.
What the Prescribing Information Actually Says
The current UK prescribing information is an important starting point.
Tirzepatide is a dual GIP and GLP 1 receptor agonist given once a week by subcutaneous injection. It affects blood glucose and also slows gastric emptying.
The UK SmPC says that tirzepatide has not been studied in people with severe gastrointestinal disease, including severe gastroparesis, and should be used with caution in these patients. Crohn's disease itself is not listed as a contraindication. The only formal contraindication in the current UK SmPC is hypersensitivity to tirzepatide or its ingredients.
This distinction is important. Having Crohn's does not automatically rule out Mounjaro, but significant gastrointestinal problems may need extra consideration before treatment is started.
What the Evidence Shows, and What It Does Not
Research on Mounjaro and Crohn's is still limited. People with IBD were not the main population studied in the large trials used to establish tirzepatide for its licensed uses, so we do not have the same level of evidence for people with Crohn's as we do for the wider population.
Some newer observational research is beginning to provide more information. One small 2024 study included 36 people with IBD who were treated with semaglutide or tirzepatide for weight loss. Most had Crohn's disease. The study found a reduction in BMI and body weight, but nausea and constipation were among the reported side effects, and the researchers said further studies are needed.
More recent research has also looked at GLP 1 medicines in people with stable IBD. A 2026 study found no significant increase in relapse risk compared with matched people who did not start a GLP 1 medicine. However, this was not a trial showing that these medicines treat Crohn's disease.
The takeaway is that the evidence is developing. It is encouraging in some areas, but there is not enough evidence to make broad claims about Mounjaro being safe or beneficial for every person with Crohn's.
The Concerns That Are Specific to Crohn's
Crohn's disease can affect different parts of the digestive system and can cause symptoms such as abdominal pain, diarrhoea, reduced appetite and weight loss.
Mounjaro can also cause gastrointestinal side effects, including nausea, diarrhoea, vomiting, constipation and abdominal pain. These effects are particularly common during dose increases and often reduce over time.
That overlap is one of the main things to consider if you have Crohn's.
Strictures and Bowel Symptoms
Some people with Crohn's develop strictures, which are narrowed areas of the bowel. Previous bowel surgery can also be relevant to your digestive health.
Mounjaro slows gastric emptying and can cause gastrointestinal symptoms. The UK prescribing information therefore recommends caution in people with severe gastrointestinal disease.
This does not mean that everyone with a Crohn's stricture will have a problem with Mounjaro. However, if you have a known narrowing, a history of bowel obstruction or significant ongoing abdominal symptoms, tell your prescriber before starting treatment.
Nutrition and Unintentional Weight Loss
Crohn's can affect appetite, food intake and, in some cases, the body's ability to absorb nutrients. Some people with Crohn's also experience weight loss without trying.
This matters when considering a medicine that can reduce appetite.
If you are losing weight without trying, speak to your IBD team or GP before starting a weight loss medicine. The cause of the weight loss should be checked rather than assuming that an appetite reducing medicine is the right next step.
Your healthcare team can also consider whether you are getting enough food, fluids and nutrients for your individual needs.
Telling a Side Effect From a Flare
This can be difficult because some Mounjaro side effects can look similar to Crohn's symptoms.
Mounjaro can cause nausea, diarrhoea, vomiting, constipation and abdominal pain. These symptoms can also happen during a Crohn's flare.
If you notice new or worsening symptoms after starting Mounjaro, do not automatically assume that they are just side effects. Contact your IBD team or prescriber if symptoms are persistent, severe or different from what you normally experience.
Your healthcare team may use your symptoms, blood tests, stool tests such as faecal calprotectin and your previous Crohn's history to work out what may be happening. Faecal calprotectin can be useful when assessing bowel inflammation, but it should be interpreted alongside your symptoms and other clinical information.
Significant diarrhoea or vomiting can also lead to dehydration. The Mounjaro prescribing information warns that gastrointestinal side effects can cause dehydration and, in some cases, a deterioration in kidney function.
Seek urgent medical advice if you have severe or persistent abdominal pain, repeated vomiting, signs of severe dehydration or symptoms that concern you.
Do Crohn's Medicines Interact With Mounjaro?
There is no general rule that common Crohn's medicines cannot be taken with Mounjaro. However, your full medication list should be checked before starting any new medicine.
Mounjaro slows gastric emptying, which can affect how quickly some oral medicines are absorbed. This is particularly relevant when a medicine has a narrow therapeutic range. Your prescriber or pharmacist can check whether any of your medicines need extra monitoring.
Medicines given by injection or infusion do not rely on the stomach for absorption, but that does not mean every medicine is automatically suitable with Mounjaro. Your healthcare team should still review your individual treatment plan.
If you take the oral contraceptive pill, there is specific guidance. For women with overweight or obesity, the UK product information advises using a non oral contraceptive method or adding a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase, because reduced effectiveness of oral contraception cannot be ruled out.
The Right Order: Get Your Medical History Reviewed First
If you have Crohn's and are considering Mounjaro for weight management, make sure your prescriber knows about your condition.
Tell them about:
- Your current Crohn's symptoms
- Any recent flares or hospital admissions
- Any bowel strictures or previous obstruction
- Previous bowel surgery
- Any unexplained weight loss
- Your current Crohn's medicines
- Any ongoing diarrhoea, vomiting or abdominal pain
- Any nutritional concerns
This information can help your prescriber decide whether Mounjaro is appropriate and whether you need any additional assessment before starting.
In the UK, NICE recommends tirzepatide as an option for managing overweight and obesity in adults who meet specific criteria. These include an initial BMI of at least 35 kg/m² and at least one weight related health condition, with lower BMI thresholds usually used for people from certain ethnic groups.
These eligibility criteria are separate from the question of whether Mounjaro is suitable for someone with Crohn's. Your medical history still needs to be considered as part of the prescribing decision.
